Report Highlights

U.S. Position in the Global Montelukast API Supply Chain

The United States is a net importer of montelukast sodium API, consuming finished-dose volume that far exceeds domestic synthesis capacity. Domestic output is limited to a small number of contract and captive facilities in New Jersey and Pennsylvania, which finish or reprocess imported intermediates. The country therefore functions as a formulation, packaging, and distribution hub rather than a primary producer, and import dependency for tablet-grade material sits near total.

India supplies the largest share of U.S.-bound montelukast API, with Hyderabad and Visakhapatnam clusters shipping through Nhava Sheva and Mumbai into New York and New Jersey distribution hubs. Ocean transit from Indian ports runs roughly five weeks. China ranks second, supplying Zhejiang and Jiangsu-based intermediates under ANDA-linked contracts, while Europe contributes higher-grade niche material and South Korea supplies specialized side-chain intermediates.

Growth Drivers for Montelukast API Trade and Production in the U.S.

Asthma and allergic rhinitis prescriptions, concentrated in Medicaid and commercial formularies, keep demand for oral montelukast steady despite the FDA's 2020 boxed warning on neuropsychiatric events. Generic substitution sustains unit volumes even as brand revenue at Merck has declined, locking in a stable base of pediatric and adult tablet demand that supports continued API imports.

Onshoring policy is the second driver. Federal supply chain initiatives and the proposed Strategic Active Pharmaceutical Ingredients Reserve are prompting Eugia US and Cipla USA to evaluate finishing and micro-synthesis lines in New Jersey and North Carolina. Each domestic line converts imported intermediates into finished API, shifting value-add and customs classification toward U.S.-origin product.

Supply Chain Risks and Trade Barriers

Raw material dependency is acute. Montelukast synthesis relies on cyclopropyl-based thiol side-chain intermediates and quinoline building blocks sourced almost exclusively from Chinese chemical parks in Shandong and Jiangsu. Few alternative suppliers exist for these intermediates at commercial scale, so environmental shutdowns or export licensing tightening in those regions propagate directly into U.S. lead times within one to two production cycles.

Tariff and regulatory exposure compounds the risk. Section 301 duties on Chinese-origin chemical inputs add cost layers, while India's loss of GSP eligibility since 2019 means standard HTS duty rates apply to Indian shipments. FDA import alerts at Newark and Charleston can halt a lot instantly, and rupee depreciation erodes Indian supplier margins, pressuring quality budgets.

Trade and Investment Opportunities in the U.S.

Import substitution is the clearest play. Finishing and micro-synthesis lines in New Jersey, Pennsylvania, and North Carolina can capture share from Indian imports, particularly under federal and state procurement preferences. Contract manufacturers with existing FDA-registered suites, such as Cambrex, can add montelukast campaigns without greenfield capital expenditure, targeting dedicated lines of 20 to 40 tonnes per year.

Inbound investment into Puerto Rico's established pharmaceutical manufacturing base offers tax-advantaged finishing sites with direct access to U.S. ports. Mexican nearshoring corridors provide an alternative intermediate hub, cutting transit from Asia by roughly three weeks. Distributors can also stage inventory at the Port of Savannah to serve Southeastern pharmacy wholesalers reliably.

Market at a Glance

Leading Market Participants

• Merck & Co.
• Cipla
• Aurobindo Pharma
• Dr. Reddy's Laboratories
• Zydus Lifesciences
• Lupin
• Glenmark Pharmaceuticals
• Hetero Labs
• Zhejiang Huahai Pharmaceutical
• Macleods Pharmaceuticals

Regulatory and Trade Policy Environment

Montelukast sodium API must comply with FDA current good manufacturing practice under 21 CFR Parts 210 and 211, and each ANDA references a Drug Master File that must match the imported lot. Imports face foreign facility registration and risk-based unannounced inspection, with import alerts applied at the port of entry when deficiencies surface. USP monograph conformance is required for tablet-grade release testing.

Trade policy sets the cost structure. Section 301 duties apply to Chinese-origin goods, while Indian shipments pay standard HTS duty rates following the lapse of GSP preferences. The Section 232 investigation into pharmaceutical imports opened in 2025 signals possible duty changes, and New Jersey and North Carolina offer state incentives for qualifying domestic finishing investment.

U.S. Montelukast API Supply Chain Outlook to 2032

Patent cliff effects are fully absorbed, so supply chain evolution will be driven by quality compliance and capacity consolidation rather than price-led switching. Indian suppliers with WHO prequalified and EU GMP-certified sites will retain share, while sub-scale Chinese producers lose U.S. contracts as FDA inspection backlogs and documentation demands rise. Vendor qualification cycles of 12 to 18 months will lock in incumbents.

Continuous manufacturing and flow chemistry adoption will reduce synthesis steps and lower the cost floor, shifting comparative advantage toward firms that invest in automated thiol-coupling lines. Domestic finishing capacity in New Jersey and North Carolina will grow, reducing import dependency from near-total toward roughly three-quarters of volume by 2032.